about
Intracellular delivery of cytochrome c by galactosylated albumin to hepatocarcinoma cells.Extracellular vesicles and their synthetic analogues in aging and age-associated brain diseases.Interaction and energy transfer studies between bovine serum albumin and CdTe quantum dots conjugates: CdTe QDs as energy acceptor probes.Synergistic Effect of Cold Atmospheric Plasma and Drug Loaded Core-shell Nanoparticles on Inhibiting Breast Cancer Cell GrowthDrug release kinetics, cell uptake, and tumor toxicity of hybrid VVVVVVKK peptide-assembled polylactide nanoparticles.Functional protein-organic/inorganic hybrid nanomaterials.Protein-polymer therapeutics: a macromolecular perspective.A sight on protein-based nanoparticles as drug/gene delivery systems.PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system.Albumin-micelles via a one-pot technology platform for the delivery of drugs.Development of antithrombotic nanoconjugate blocking integrin α2β1-collagen interactions.Strategies for Preparing Albumin-based Nanoparticles for Multifunctional Bioimaging and Drug Delivery.A Versatile Method to Prepare Protein Nanoclusters for Drug Delivery.Drug Delivery Vehicles Based on Albumin-Polymer Conjugates.Supramolecular nanoparticle carriers self-assembled from cyclodextrin- and adamantane-functionalized polyacrylates for tumor-targeted drug deliveryPhotoresponsive amphiphilic azobenzene–PEG self-assembles to form supramolecular nanostructures for drug delivery applicationsNanomaterials engineering for drug delivery: a hybridization approachFully degradable protein nanocarriers by orthogonal photoclick tetrazole–ene chemistry for the encapsulation and release
P2860
Q35147280-57107C39-4E80-4E0C-8E31-A9334F9B715AQ36081720-B70143B7-E90D-401E-8927-553F7905FCA7Q36181033-59F8E667-7DBA-4EC1-9314-C7C448E3B850Q36621421-069EFB24-E13B-42BE-96A7-5FE7DBF5404DQ36767228-12B58C27-1D43-4688-A531-D70EE7D941BBQ38077728-69AB766C-B180-424D-A2A7-6588972C8792Q38555997-EBA130D1-A971-4F79-AE43-1BF8075E1A9EQ38573478-DB43DF2D-1830-4EF3-B1FB-8FB7F133B3BEQ38954044-A9E0B6A6-D4DD-4C98-899E-4FD50D9F8D90Q38996884-EE20A2AA-6BAA-4EB7-BE69-C7A7F552316DQ42565906-AA672B77-6C54-4586-BECB-BC0315AD0D8BQ43142557-EC58BE0A-4EDB-4664-B55B-C7B5AFFB56CCQ47224899-71B33219-E03A-4CD6-8859-A409AA0A124BQ51465915-C52F3282-9626-4A1D-80E2-3DABF2AF5918Q57348013-8E415A32-FDEF-445D-BFA4-DB781427BE0AQ57366667-2AD526B8-F8C4-4E1C-81D3-8220548154BFQ57367599-7F6C1B84-4EE2-444D-B6CC-A00545F37FE2Q57947032-B2DCBD52-466F-4ADA-8931-8B17A0995BCA
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Protein-polymer hybrid nanoparticles for drug delivery.
@en
Protein-polymer hybrid nanoparticles for drug delivery.
@nl
type
label
Protein-polymer hybrid nanoparticles for drug delivery.
@en
Protein-polymer hybrid nanoparticles for drug delivery.
@nl
prefLabel
Protein-polymer hybrid nanoparticles for drug delivery.
@en
Protein-polymer hybrid nanoparticles for drug delivery.
@nl
P2093
P2860
P356
P1433
P1476
Protein-polymer hybrid nanoparticles for drug delivery.
@en
P2093
Evgenios Neofytou
Jiandu Lei
Ramin E Beygui
Richard N Zare
P2860
P304
P356
10.1002/SMLL.201200889
P577
2012-08-09T00:00:00Z